Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classificação em ações #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Preço da ação
$0.00185055
Valor de mercado
$48.29K
Variação (1 dia)
-3.55%
Variação (1 ano)
30.31%
País
GB
Negociar Nuformix plc (NFX)

Categoria

Lucros da Nuformix plc (NFX)
Lucros em Mar 2026 TTM: $-857.89K
De acordo com os últimos relatórios financeiros da Nuformix plc, os ganhos atuais da empresa são de $-857.89K. Em 2024, a empresa teve ganhos de $-4.88M, uma diminuição em relação a aos ganhos de 2023, que foram de $-754.56K. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Nuformix plc de 2014 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$5.27B -614,967.33%
US
$-3.09B 359,735.34%
US
$-4.02B 468,046.88%
AU
$1.95B -227,477.01%
NL
- -
CH